Agentix Corp.
AGTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8M
Close$
$-0.01
116.6% downside
Current Fair Value
116.6% downsideOvervalued by 116.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.80 Million |
|---|---|
| Enterprise Value | $2.80 Million |
| Earnings per Share | $-0.01 |
| Beta | 0.77 |
| Outstanding Shares | 40,066,951 |
Return
| Return on Equity | 11.24% |
|---|---|
| Return on Assets | -1098647.37% |
| Return on Invested Capital | 9.16% |
Valuation & Multiples
| P/E Ratio | -6.73 |
|---|---|
| PEG | 18.35 |
| Price to Sales | - |
| Price to Book Ratio | -0.05 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.24 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 9, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Agentix Corp.
2 employees
CEO: Riazul Huda
Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a periph...